Prostate cancer is the only known disease of the prostate that displays such a substantial decrease in tissue zinc content and neither prostatitis nor benign prostatic hyperplasia are associated with this phenotype. 19F-based iCEST MRI probe TF-BAPTA was used to show clearly a detectable difference in zinc concentration between normal and malignant prostate cell lines, and normal prostate cells with a downregulated ZIP1 transporter. Via an orthotopic prostate cancer mouse model, the feasibility of iCEST MRI to distinguish normal mouse prostate and cancerous prostate has been verified. Hence, iCEST MRI may have potential to non-invasively monitor the early malignant transformation in prostate cancer.
This abstract and the presentation materials are available to members only; a login is required.